• Je něco špatně v tomto záznamu ?

Treatment of ichthyosis lamellaris using a series of herbal skin care products family

M. Tirant, P. Bayer, J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, F. Novotny, MG. Roccia, GK. Maximov, K. França, T. Lotti,

. 2016 ; 30 (2 Suppl 3) : 65-72.

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001370

Lamellar ichthyosis (LI) is a genetically heterogeneous group of disorders of keratinization that are inherited in an autosomal recessive fashion, occurring in approximately 1 in 300,000 live births. The treatment of the large, dark, plate-like scales that characterize the classic manifestation of the disease are still a challenge. The aim of this study was to evaluate the efficacy and tolerability of Dr. Michaels® skin-care products for the management of LI. A multi-centre European prospective study was conducted, including 10 patients (3 female/7 male) with lamellar ichthyosis, aged 38-54 years old (mean age: 46). Each patient had been treated with emollients plus other different systemic therapies, such as corticosteroids, Cyclosporin A or retinoids in the past. All patients were treated with Dr Michaels® product family including both topical and oral herbal supplements. The topical treatments used were the cleansing gel, activator formula and ointment. The oral medications were PSC 200, PSC 400 and PSC 900. Within 3 weeks of initiation of treatment, there were improvements observed on the skin including a reduction in scaling, fissuring, and intensity in erythema and pruritus with thinning of the hyperkeratotic plate. After 12-15 weeks, most of the plates and scales had been removed to reveal a normalised skin colour. Evidence of hair, eyelash and eyebrow growth was observed. There was partial nail resolution with a reduction in subungual hyperkeratosis. No adverse reactions were observed. Our patients showed excellent symptomatic response to treatment within a 14-week period, follow-up by an on-going regular assessment on a quarterly basis. The results show that Dr Michaels® product family is an effective and safe treatment option for LI.

000      
00000naa a2200000 a 4500
001      
bmc19001370
003      
CZ-PrNML
005      
20190308125648.0
007      
ta
008      
190107s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)27498660
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Tirant, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
245    10
$a Treatment of ichthyosis lamellaris using a series of herbal skin care products family / $c M. Tirant, P. Bayer, J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, F. Novotny, MG. Roccia, GK. Maximov, K. França, T. Lotti,
520    9_
$a Lamellar ichthyosis (LI) is a genetically heterogeneous group of disorders of keratinization that are inherited in an autosomal recessive fashion, occurring in approximately 1 in 300,000 live births. The treatment of the large, dark, plate-like scales that characterize the classic manifestation of the disease are still a challenge. The aim of this study was to evaluate the efficacy and tolerability of Dr. Michaels® skin-care products for the management of LI. A multi-centre European prospective study was conducted, including 10 patients (3 female/7 male) with lamellar ichthyosis, aged 38-54 years old (mean age: 46). Each patient had been treated with emollients plus other different systemic therapies, such as corticosteroids, Cyclosporin A or retinoids in the past. All patients were treated with Dr Michaels® product family including both topical and oral herbal supplements. The topical treatments used were the cleansing gel, activator formula and ointment. The oral medications were PSC 200, PSC 400 and PSC 900. Within 3 weeks of initiation of treatment, there were improvements observed on the skin including a reduction in scaling, fissuring, and intensity in erythema and pruritus with thinning of the hyperkeratotic plate. After 12-15 weeks, most of the plates and scales had been removed to reveal a normalised skin colour. Evidence of hair, eyelash and eyebrow growth was observed. There was partial nail resolution with a reduction in subungual hyperkeratosis. No adverse reactions were observed. Our patients showed excellent symptomatic response to treatment within a 14-week period, follow-up by an on-going regular assessment on a quarterly basis. The results show that Dr Michaels® product family is an effective and safe treatment option for LI.
650    _2
$a dospělí $7 D000328
650    12
$a potravní doplňky $7 D019587
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lamelární ichtyóza $x dietoterapie $x terapie $7 D017490
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a masti $x aplikace a dávkování $x terapeutické užití $7 D009824
650    _2
$a fytoterapie $x metody $7 D008517
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kůže $x účinky léků $7 D012867
650    _2
$a péče o kůži $x metody $7 D017592
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bayer, P $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Hercogová, J $u 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Fioranelli, M $u Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy.
700    1_
$a Gianfaldoni, S $u Dermatological Department University of Pisa, Pisa, Italy.
700    1_
$a Chokoeva, A A $u Onkoderma - Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria.
700    1_
$a Tchernev, G $u Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
700    1_
$a Wollina, U $u Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
700    1_
$a Novotny, F $u PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic.
700    1_
$a Roccia, M G $u University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
700    1_
$a Maximov, G K $u Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency; Sofia, Bulgaria.
700    1_
$a França, K $u Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.
700    1_
$a Lotti, T $u Chair of Dermatology, University of Rome G. Marconi Rome, Italy.
773    0_
$w MED00008336 $t Journal of biological regulators and homeostatic agents $x 0393-974X $g Roč. 30, č. 2 Suppl 3 (2016), s. 65-72
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27498660 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190308130004 $b ABA008
999    __
$a ok $b bmc $g 1364067 $s 1039493
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 30 $c 2 Suppl 3 $d 65-72 $i 0393-974X $m Journal of Biological Regulators & Homeostatic Agents $n J Biol Regul Homeost Agents $x MED00008336
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace